AKT1 and small cell lung carcinoma: Notably, signaling pathways known to drive tumorigenesis in SCLC and currently investigated in targeted therapy trials (DLL3-targeting molecules for the NOTCH pathway or PI3KCA/AKT inhibitors for the MAPK pathway) were specifically implicated in relapsed CD56+ CTC19,20.